Sulbactam-durlobactam from Innoviva should be approved by the US FDA to treat ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.

Sulbactam-durlobactam from Innoviva should be approved by the US FDA to treat ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.

The US Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted 12-0 in favour of approval of sulbactam-durlobactam for the treatment of adults with ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia caused by susceptible strains, according to…